// App-Quantinova.ai

3 : The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (cosmic-hf)

Researchers

Presenter

  • Tor Biering-Srensen

Principal Investigators

  • Alexander Papolos

  • John R. Teerlink

  • G. Michael Felker

  • John J.V. McMurray

  • Jason C. Legg

  • Fady I. Malik

  • Narimon Honarpour

  • Christopher E. Kurtz

  • Scott D. Solomon

Medical Centers

  • Herlev and Gentofte Hosp, Copenhagen, Denmark

  • Medstar Washington Hosp Ctr, Washington, DC

  • San Francisco VA Medical Center, San Francisco, CA

  • Duke University College of Medicine, Durham, NC

  • British Heart Fndn Cardiovascular Res Ctr, Univ of Glasgow, Glasgow, United Kingdom

  • Amgen Inc, Thousand Oaks, CA

  • Cytokinetics, Inc., South San Francisco, CA

  • Amgen Inc, Thousand Oaks, CA

  • Brigham and Women's Hospital, Brookline, MA

Locations

  • Denmark

  • United States

  • United Kingdom

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Congestive heart failure

Biomarkers

  • Carboxypeptidase B1

Drug/Treatment

  • omecamtiv mecarbil (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved